298 related articles for article (PubMed ID: 35968876)
21. Risk factors for respiratory syncytial virus bronchiolitis hospitalizations in children with chronic diseases.
Shmueli E; Goldberg O; Mei-Zahav M; Stafler P; Bar-On O; Levine H; Steuer G; Mussaffi H; Gendler Y; Blau H; Prais D
Pediatr Pulmonol; 2021 Jul; 56(7):2204-2211. PubMed ID: 33913611
[TBL] [Abstract][Full Text] [Related]
22. Impact of severe disease caused by respiratory syncytial virus in children living in developed countries.
Simoes EA; Carbonell-Estrany X
Pediatr Infect Dis J; 2003 Feb; 22(2 Suppl):S13-8; discussion S18-20. PubMed ID: 12671448
[TBL] [Abstract][Full Text] [Related]
23. Respiratory syncytial virus disease in preterm infants in the U.S. born at 32-35 weeks gestation not receiving immunoprophylaxis.
Ambrose CS; Anderson EJ; Simões EA; Wu X; Elhefni H; Park CL; Sifakis F; Groothuis JR
Pediatr Infect Dis J; 2014 Jun; 33(6):576-82. PubMed ID: 24622396
[TBL] [Abstract][Full Text] [Related]
24. Respiratory syncytial virus bronchiolitis in congenital diaphragmatic hernia: A systematic review of prevalence rates and palivizumab prophylaxis.
Lewis L; Sinha I; Losty PD
Pediatr Pulmonol; 2022 Jan; 57(1):239-244. PubMed ID: 34617409
[TBL] [Abstract][Full Text] [Related]
25. Update on respiratory syncytial virus hospitalizations among U.S. preterm and term infants before and after the 2014 American Academy of Pediatrics policy on immunoprophylaxis: 2011-2017.
Fergie J; Goldstein M; Krilov LR; Wade SW; Kong AM; Brannman L
Hum Vaccin Immunother; 2021 May; 17(5):1536-1545. PubMed ID: 33090914
[TBL] [Abstract][Full Text] [Related]
26. Admission to the intensive care unit for respiratory syncytial virus bronchiolitis: a national survey before palivizumab use.
Prais D; Schonfeld T; Amir J;
Pediatrics; 2003 Sep; 112(3 Pt 1):548-52. PubMed ID: 12949282
[TBL] [Abstract][Full Text] [Related]
27. Outcomes of Infants Receiving Palivizumab Prophylaxis for Respiratory Syncytial Virus in Canada and Italy: An International, Prospective Cohort Study.
Manzoni P; Paes B; Lanctôt KL; Dall'Agnola A; Mitchell I; Calabrese S; Maule M; Girardi E; Harimoto T; Li A
Pediatr Infect Dis J; 2017 Jan; 36(1):2-8. PubMed ID: 27649365
[TBL] [Abstract][Full Text] [Related]
28. Clinical burden of severe respiratory syncytial virus infection during the first 2 years of life in children born between 2000 and 2011 in Scotland.
Thwaites R; Buchan S; Fullarton J; Morris C; Grubb E; Rodgers-Gray B; Coutts J
Eur J Pediatr; 2020 May; 179(5):791-799. PubMed ID: 31912234
[TBL] [Abstract][Full Text] [Related]
29. Hospital admissions and need for mechanical ventilation in children with respiratory syncytial virus before and during the COVID-19 pandemic: a Danish nationwide cohort study.
Nygaard U; Hartling UB; Nielsen J; Vestergaard LS; Dungu KHS; Nielsen JSA; Sellmer A; Matthesen AT; Kristensen K; Holm M
Lancet Child Adolesc Health; 2023 Mar; 7(3):171-179. PubMed ID: 36634692
[TBL] [Abstract][Full Text] [Related]
30. Respiratory syncytial virus hospitalization trends in infants with chronic lung disease of infancy, 1998-2008.
Groothuis JR; Fryzek JP; Makari D; Steffey D; Martone WJ
Clin Epidemiol; 2011; 3():245-50. PubMed ID: 22003308
[TBL] [Abstract][Full Text] [Related]
31. Impact of the 2014 American Academy of Pediatrics Immunoprophylaxis Policy on the Rate, Severity, and Cost of Respiratory Syncytial Virus Hospitalizations among Preterm Infants.
Krilov LR; Fergie J; Goldstein M; Brannman L
Am J Perinatol; 2020 Jan; 37(2):174-183. PubMed ID: 31430818
[TBL] [Abstract][Full Text] [Related]
32. Respiratory syncytial virus hospitalizations in US preterm infants after the 2014 change in immunoprophylaxis guidance by the American Academy of Pediatrics.
Krilov LR; Anderson EJ
J Perinatol; 2020 Aug; 40(8):1135-1144. PubMed ID: 32499597
[TBL] [Abstract][Full Text] [Related]
33. Respiratory Syncytial Virus Disease: Immunoprophylaxis Policy Review and Public Health Concerns in Preterm and Young Infants.
Staebler S; Blake S
Policy Polit Nurs Pract; 2021 Feb; 22(1):41-50. PubMed ID: 33050785
[TBL] [Abstract][Full Text] [Related]
34. Hospitalization for bronchiolitis in children aged ≤ 1year, Southern Italy, year 2021: need for new preventive strategies?
Baldassarre ME; Loconsole D; Centrone F; Caselli D; Martire B; Quartulli L; Acquafredda A; D'Amato G; Maffei G; Latorre G; Riganti A; Di Noia M; Chironna M; Laforgia N
Ital J Pediatr; 2023 Jun; 49(1):66. PubMed ID: 37280662
[TBL] [Abstract][Full Text] [Related]
35. The increasing age of respiratory syncytial virus-related hospitalisation during COVID-19 pandemic in Lyon was associated with reduced hospitalisation costs.
Roy Á; Polazzi S; Ploin D; Gillet Y; Javouhey E; Lina B; ; Myard-Dury AF; Couray-Targe S; Duclos A; Casalegno JS
Vaccine; 2023 Jun; 41(25):3796-3800. PubMed ID: 37198017
[TBL] [Abstract][Full Text] [Related]
36. Respiratory syncytial virus (RSV) infection in children with medical complexity.
Lim A; Butt ML; Dix J; Elliott L; Paes B
Eur J Clin Microbiol Infect Dis; 2019 Jan; 38(1):171-176. PubMed ID: 30374685
[TBL] [Abstract][Full Text] [Related]
37. Trends in Respiratory Syncytial Virus and Bronchiolitis Hospitalization Rates in High-Risk Infants in a United States Nationally Representative Database, 1997-2012.
Doucette A; Jiang X; Fryzek J; Coalson J; McLaurin K; Ambrose CS
PLoS One; 2016; 11(4):e0152208. PubMed ID: 27050095
[TBL] [Abstract][Full Text] [Related]
38. Six-monthly palivizumab prophylaxis effectively reduced RSV-associated hospitalization rates of preterm infants in a subtropical area: a population-based cohort study.
Lin YJ; Chung CH; Chi H; Lin CH
Pediatr Res; 2019 Nov; 86(5):628-634. PubMed ID: 31261371
[TBL] [Abstract][Full Text] [Related]
39. Clinical and economic hospital burden of acute respiratory infection (BARI) due to respiratory syncytial virus in Spanish children, 2015-2018.
Martinón-Torres F; Carmo M; Platero L; Drago G; López-Belmonte JL; Bangert M; Díez-Domingo J
BMC Infect Dis; 2023 Jun; 23(1):385. PubMed ID: 37291530
[TBL] [Abstract][Full Text] [Related]
40. Respiratory Syncytial Virus Immunoprophylaxis with Palivizumab: 12-Year Observational Study of Usage and Outcomes in Canada.
Mitchell I; Li A; Bjornson CL; Lanctot KL; Paes BA;
Am J Perinatol; 2022 Nov; 39(15):1668-1677. PubMed ID: 33657636
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
